-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
Shijiazhuang Fourth Pharmaceutical Group’s Pentoxifylline Injection and Ipratropium Bromide Solution for Inhalation Have Been Approved.
Category:
Time：2022-10-11
Recently, two products—Pentoxifylline Injection (5 ml: 0.1 g) and Ipratropium Bromide Solution for Inhalation (2 ml: 0.5 mg and 2 ml: 0.25 mg)—developed by Shijiazhuang Fourth Pharmaceutical Group have simultaneously received drug registration certificates from the National Medical Products Administration on the same day. These products are deemed to have passed the evaluation of bioequivalence and therapeutic equivalence for generic drugs. Notably, Pentoxifylline Injection (5 ml: 0.1 g) is the first product from a Chinese pharmaceutical company to receive such approval.
In the golden autumn season, Shijiazhuang Fourth Pharmaceutical has reaped abundant rewards from its scientific research and innovation efforts. Recently, two product varieties—hexahydrococoine injection (5 ml: 0.1 g) and ipratropium bromide solution for inhalation (2 ml: 0.5 mg and 2 ml: 0.25 mg)—each available in three different specifications, received drug registration certificates from the National Medical Products Administration on the same day. These products are also deemed to have passed the evaluation of bioequivalence and therapeutic equivalence for generic drugs. Notably, the hexahydrococoine injection (5 ml: 0.1 g) is the first product from a Chinese pharmaceutical company to receive such approval.
It is reported that Pentoxifylline Injection is primarily used for the treatment of peripheral arterial disease and inner ear circulatory disorders, while Ipratropium Bromide Solution for Inhalation is mainly used for the relief of bronchospasm caused by chronic obstructive pulmonary disease (including chronic bronchitis, emphysema, and asthma).
In recent years, Shijiazhuang Fourth Pharmaceutical Group’s innovative strengths have become increasingly prominent. Since the beginning of this year, the group has obtained 35 product approvals of various types, including 26 approval for finished dosage forms. To date, a total of 31 drug varieties and 41 specifications have either passed or been deemed to have passed the National Generic Drug Quality and Efficacy Consistency Evaluation. The group ranks among the top pharmaceutical companies nationwide in both the efficiency and volume of developing specialized generic drugs, and its strong innovation capabilities continue to drive the ongoing optimization and enhancement of its product portfolio and product hierarchy.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license